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Introduction: We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to
the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and
a modest reduction in risk of breast cancer in women age ≤50 years.
Methods: We further investigated the association of rs10235235 with breast cancer risk in a large case control study of
47,346 cases and 47,570 controls from 52 studies participating in the Breast Cancer Association Consortium. Genotyping
of rs10235235 was conducted using a custom Illumina Infinium array. Stratified analyses were conducted to determine
whether this association was modified by age at diagnosis, ethnicity, age at menarche or tumor characteristics.
Results: We confirmed the association of rs10235235 with breast cancer risk for women of European ancestry but found
no evidence that this association differed with age at diagnosis. Heterozygote and homozygote odds ratios (ORs) were
OR = 0.98 (95% CI 0.94, 1.01; P = 0.2) and OR = 0.80 (95% CI 0.69, 0.93; P = 0.004), respectively (Ptrend = 0.02). There was
no evidence of effect modification by tumor characteristics. rs10235235 was, however, associated with age at menarche
in controls (Ptrend = 0.005) but not cases (Ptrend = 0.97). Consequently the association between rs10235235 and breast
cancer risk differed according to age at menarche (Phet = 0.02); the rare allele of rs10235235 was associated with a
reduction in breast cancer risk for women who had their menarche age ≥15 years (ORhet = 0.84, 95% CI 0.75, 0.94;
ORhom = 0.81, 95% CI 0.51, 1.30; Ptrend = 0.002) but not for those who had their menarche age ≤11 years (ORhet = 1.06,
95% CI 0.95, 1.19, ORhom = 1.07, 95% CI 0.67, 1.72; Ptrend = 0.29).
Conclusions: To our knowledge rs10235235 is the first single nucleotide polymorphism to be associated with both
breast cancer risk and age at menarche consistent with the well-documented association between later age at menarche
and a reduction in breast cancer risk. These associations are likely mediated via an effect on circulating hormone levels.Introduction
Family history is a well-established risk factor for breast can-
cer. First-degree relatives of women with breast cancer have
an approximately twofold increased risk of developing the
disease relative to the general population [1]. Twin studies
are consistent with this familial clustering having, at least in
part, a genetic origin [2,3]. Mutations in high-risk suscepti-
bility genes (mainly BRCA1 and BRCA2) explain most large
multiple-case families, but account for only 15 to 20% of the
excess familial risk [4]. Genome-wide association studies
[5,6] have identified more than 70 common variants that are
associated with breast cancer susceptibility but they account
for only another approximately 15% of the excess familial
risk. The so-called ‘missing heritability’ may be explained by
common variants with very small effects and/or by rarer
variants with larger effects, neither of which can be identi-
fied by current genome-wide association studies. A statisti-
cally efficient alternative is to increase power by trying to
identify variants associated with known quantitative pheno-
typic markers of susceptibility to breast cancer [7], and then
to test them for association with breast cancer risk. This
approach might also improve our understanding of the bio-
logical mechanisms involved in breast cancer pathogenesis.Endogenous sex hormones are well-established risk
factors for breast cancer in postmenopausal women [8];
the evidence in premenopausal women is less consistent,
with some, but not all, studies suggesting an association
between higher circulating levels of estrogens and in-
creased breast cancer risk [9-17]. Genetic factors influ-
ence the levels of endogenous sex hormones [18] and
therefore single nucleotide polymorphisms (SNPs) in
genes regulating these hormonal pathways are good can-
didates for being breast cancer predisposition variants.
We have previously studied 642 SNPs tagging 42 genes
that might influence sex hormone levels in 729 healthy
premenopausal women of European ancestry in relation
to cyclic variations in oestrogen levels during the men-
strual cycle. We found that the minor allele of rs10273424,
which maps 50 kb 3′ to CYP3A5, was associated with a
reduction of 22% (95% confidence interval (CI) = –28%, –
15%; P = 10−9) in levels of urinary oestrone glucuronide, a
metabolite that is highly correlated with serum oestradiol
levels [19]. Analysis of 10,551 breast cancer cases and
17,535 controls of European ancestry demonstrated that
the minor allele of rs10235235, a proxy for rs10273424
(r2 = 1.0), was also associated with a weak reduction in
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younger at diagnosis (odds ratio (OR) = 0.91, 95% CI =
0.83, 0.99; P = 0.03) [19].
The aim of the present study was to further investigate
an association between rs10235235 and breast cancer risk
using a much larger set of subjects – the Breast Cancer
Association Consortium (BCAC) – comprising data from
49 additional studies, and to assess whether there was evi-
dence of effect modification by age at diagnosis, ethnicity,
age at menarche or tumour characteristics.
Materials and methods
Sample selection
Samples for the case–control analyses were drawn from
52 studies participating in the BCAC: 41 studies from
populations of predominantly European ancestry, nine
studies of Asian ancestry and two studies of African-
American ancestry. The majority were population-based
or hospital-based case–control studies, but some studies
were nested in cohorts, selected samples by age, over-
sampled for cases with a family history or selected sam-
ples on the basis of tumour characteristics (Table S1 in
Additional file 1). Studies provided ~2% of samples in
duplicate for quality control purposes (see below). Study
subjects were recruited on protocols approved by the In-
stitutional Review Boards at each participating institu-
tion, and all subjects provided written informed consent
(Additional file 2).
Genotyping and post-genotyping quality control
Genotyping for rs10235235 was carried out as part of a
collaboration between the BCAC and three other con-
sortia (the Collaborative Oncological Gene-environment
Study (COGS)). Full details of SNP selection, array de-
sign, genotyping and post-genotyping quality control
have been published [5]. Briefly, three categories of SNPs
were chosen for inclusion in the array: SNPs selected on
the basis of pooled genome-wide association study data;
SNPs selected for the fine-mapping of published risk
loci; and candidate SNPs selected on the basis of previ-
ous analyses or specific hypotheses. rs10235235 was a
candidate SNP selected on the basis of our previous ana-
lyses [19].
For the COGS project overall, genotyping of 211,155
SNPs in 114,225 samples was conducted using a custom
Illumina Infinium array (iCOGS; Illumina, San Diego,
CA, USA) in four centres. Genotypes were called using
Illumina’s proprietary GenCall algorithm. Standard quality
control measures were applied across all SNPs and all
samples genotyped as part of the COGS project. Samples
were excluded for any of the following reasons: genotypi-
cally not female XX (XY, XXY or XO, n = 298); overall
call rate <95% (n = 1,656); low or high heterozygosity
(P < 10−6, separately for individuals of European, Asianand African-American ancestry, n = 670); individuals not
concordant with previous genotyping within the BCAC
(n = 702); individuals where genotypes for the duplicate
sample appeared to be from a different individual (n = 42);
cryptic duplicates within studies where the phenotypic data
indicated that the individuals were different, or between
studies where genotype data indicated samples were dupli-
cates (n = 485); first-degree relatives (n = 1,981); phenotypic
exclusions (n = 527); or concordant replicates (n = 2,629).
Ethnic outliers were identified by multidimensional
scaling, combining the iCOGS array data with the three
Hapmap2 populations, based on a subset of 37,000 un-
correlated markers that passed quality control (includ-
ing ~1,000 selected as ancestry informative markers).
Most studies were predominantly of a single ancestry
(European or Asian), and women with >15% minority
ancestry, based on the first two components, were ex-
cluded (n = 1,244). Two studies from Singapore (SGBCC)
and Malaysia (MYBRCA; see Table S1 in Additional file 1
for all full study names) contained a substantial fraction of
women of mixed European/Asian ancestry (probably of
South Asian ancestry). For these studies, no exclusions for
ethnic outliers were made, but principal components ana-
lysis (see below) was used to adjust for inflation in these
studies. Similarly, for the two African-American studies
(NBHS and SCCS), no exclusions for ethnic outliers were
made.
Principal component analyses were carried out separ-
ately for the European, Asian and African-American
subgroups, based on a subset of 37,000 uncorrelated
SNPs. For the analyses of European subjects, we in-
cluded the first six principal components as covariates,
together with a seventh component derived specific to
one study (LMBC) for which there was substantial infla-
tion not accounted for by the components derived from
the analysis of all studies. Addition of further principal
components did not reduce inflation further. Two princi-
pal components were included for the studies conducted
in Asian populations and two principal components were
included for the African-American studies.
For the main analyses of rs10235235 and breast can-
cer risk, we excluded women from three studies
(BBCS, BIGGS and UKBGS) that were genotyped in the
hypothesis-generating study (n = 5,452) [19] and women
with non-invasive cancers (ductal carcinoma in situ/lobular
carcinoma in situ, n = 2,663) or cancers of uncertain status
(n = 960)). After exclusions there were 47,346 invasive
breast cancer case samples and 47,570 control samples
from 49 studies (38 from populations of predominantly
European ancestry, nine Asian and two African-American)
used in the analysis (Tables S1 and S2 in Additional file 1).
After quality control exclusions (above) the call rate for
rs10235235 was 100% (one no call in 94,916 samples), and
for the controls there was no evidence of deviation from
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ing studies (Table S2 in Additional file 1).
We did not test for an association between rs10235235
and age at menarche in our hypothesis-generating study
[19]. Therefore, to maximise our power to detect an as-
sociation, we included menarche data from BBCS cases
(n = 2,508) and controls (n = 1,650) and from UKBGS
cases (n = 3,388) and controls (n = 4,081) in this ana-
lysis. Age at menarche was not available for samples
from BIGGS. Full details of genotyping of rs10235235
in BBCS and UKBGS samples have been published
previously [19]. Briefly, genotyping was carried out
using competitive allele-specific polymerase chain reac-
tion KASPar chemistry (KBiosciences Ltd, Hoddesdon,
Hertfordshire, UK). Call rates were 98.0% (BBCS) and
96.6% (UKBGS); there was no evidence for deviation from
Hardy–Weinberg equilibrium (P = 0.29 (BBCS); P = 0.92
(UKBGS)), and the duplicate concordance based on a 1%
(BBCS) and 5% (UKBGS) random sample of duplicates
was 100% for both studies.
Statistical analysis
We estimated per-allele and genotypic log odds ratios
(ORs) for the European, Asian and African-American
subgroups separately using logistic regression, adjusted
for principal components and study [5]. To test for de-
parture from a multiplicative model we compared multi-
plicative and unconstrained models using a one degree
of freedom likelihood ratio test. Heterogeneity in ORs
between studies within each subgroup (European, Asian
and African-American), and between subgroups, was assessed
using the Cochrane Q statistic and quantified using the
I2 measure [20].
Analyses stratified by oestrogen receptor status (+/–),
progesterone receptor status (+/–), morphology (ductal
or lobular), grade (1,2,3), lymph node involvement (+/–)
or age at diagnosis (≤50 and >50 years) were restricted
to studies of European ancestry due to the small number
of studies of Asian and African-American ancestry. In
addition, studies were excluded if they had selected cases
on the basis of the stratifying variable, or had collected
data on that variable for less than 5% of cases or less
than 10 cases in total. Availability of data for each of the
stratifying variables in each study is shown in Table S3
in Additional file 1. To assess the relationship between
each of the stratifying variables and genotype, stratum-
specific ORs were calculated using logistic regression.
Cases in each stratum were compared with all control
subjects, adjusted for study and principal components.
Case-only logistic regression was used to test for hetero-
geneity between strata (binary stratifying variables) or
across strata (stratifying variables with three or more
strata). P values were estimated using likelihood ratio
tests with one degree of freedom.We assessed whether rs10235235 was associated with
age at menarche in cases and controls separately. Studies
that had not collected data on age at menarche in both
cases and controls were excluded (Table S4 in Additional
file 1). We used linear regression, adjusted for principal
components and study, to estimate the relationship be-
tween age at menarche (years) and rs10235235 genotype
(0, 1, 2 rare alleles) and logistic regression adjusted for
principal components and study to estimate the associ-
ation between age at menarche and breast cancer risk.
To test for effect modification of an association between
rs10235235 and breast cancer risk by age at menarche,
we used logistic regression adjusted for principal compo-
nents, study and age at menarche (grouped as ≤11, 12,
13, 14 and ≥15 years) with and without an interaction
term(s). We considered four models: no interaction
(zero interaction terms); assuming a linear interaction
between genotype and menarche group (one interaction
term); assuming a linear interaction between genotype
and menarche group but allowing the linear term to dif-
fer between women who were heterozygous and those
who were homozygous for the rare allele (two inter-
action terms); and one interaction term for each possible
genotype/menarche group combination (eight interaction
terms). Nested models were compared using likelihood
ratio tests. All statistical analyses were performed using
STATA version 11.0 (StataCorp, College Station, TX,
USA). All P values reported are two-sided.
Results
The case–control analysis comprised genotype data for
47,346 invasive breast cancer cases and 47,569 controls
from 49 studies, including 80,518 (84.8%) subjects of self-
reported European ancestry, 12,419 (13.1%) of self-
reported Asian ancestry and 1,978 (2.1%) of self-reported
African-American ancestry. The mean (± standard devi-
ation) age at diagnosis was 56.1 (± 11.6) years for European
cases, 51.1 (± 10.5) years for Asian cases and 53.1 (± 10.7)
years for African-American cases. There were ethnic
differences in the estimated minor allele frequency
(MAF) of rs10235235 (Q = 7317.1, two degrees of free-
dom; P for heterogeneity (Phet) = 0). The overall MAF
for European control women was 0.089 (95% CI = 0.087,
0.091), but with strong evidence of between-study hetero-
geneity (Phet = 1 × 10
−22) that was accounted for by the
three Finnish studies (HEBCS, MAF = 0.15; KBCP, MAF =
0.21; and OBCS, MAF = 0.15; Phet = 0.01); no evidence
of heterogeneity remained after taking account of these
studies (MAF = 0.087 (95% CI = 0.085, 0.089); Phet = 0.23).
Relative to Europeans, the overall MAF was higher for
African-Americans (0.213, 95% CI = 0.195, 0.232; Phet =
0.26) but much lower for Asians (0.002; 95% CI =
0.001, 0.002), with strong evidence of between-study
heterogeneity for the latter (Phet = 4 × 10
−14).
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association between rs10235235 and breast cancer risk for
women of European ancestry, with an estimated per-allele
OR of 0.96 (95% CI = 0.93, 0.99; P for linear trend (Ptrend) =
0.02). Genotype-specific ORs were 0.98 (95% CI =
0.94, 1.01; P = 0.21) for AG versus AA (Figure 1A) and
0.80 (95% CI = 0.69, 0.93; P = 0.004) for GG versus AA
(Figure 1B), with no evidence of between-study hetero-
geneity for either OR estimate (Phet = 0.44, I
2 = 1.9%
and Phet = 0.76, I
2 = 0.0% for heterozygote and homo-
zygote OR estimates respectively). There was, however,
marginally significant evidence that the genotypic OR esti-
mates departed from those expected under a multiplicative
model with the inverse association of the GG genotype be-
ing more than the square of that of the AG genotype (test
for deviation from multiplicative model, P = 0.04).
Data for rs10235235 in women of Asian or African-
American ancestry were more limited, with just two
African-American studies (1,046 cases and 932 controls)
and nine Asian studies (5,795 cases and 6,624 controls).
In addition, this SNP was sufficiently rare in Asian pop-
ulations (MAF = 0.002) that we were unable to estimate
the heterozygote OR in two Asian studies (SEBCS, one
carrier among 1,114 cases and no carriers among 1,129
controls; TWBCS, one carrier among 236 controls and no
carriers among 774 cases; Table S2 in Additional file 1)
and we could not estimate a homozygote OR for anyOverall  (I-squared = 1.9%, phet = 0.436)
OBCS
HEBCS
MEC
MCCS
GENICA
CGPS
RBCS
ABCFS
SZBCS
OSU
MBCSG
RPCI
BBCC
SEARCH
SKKDKFZS
MTLGEBCS
Study
BSUCH
DEMOKRITOS
SBCS
MCBCS
NBCS
CNIO-BCS
KBCP
ORIGO
CTS
CECILE
OFBCR
ESTHER
NBHS
pKARMA
ABCS
PBCS
kConFab/AOCS
LMBC
MARIE
HMBCS
KARBAC
SASBAC
500
1517
705
614
465
2811
620
790
303
207
189
47
554
9097
134
489
Cases
815
413
751
1546
22
867
411
335
68
900
1156
471
125
4553
1256
519
410
2616
1656
688
722
1163
414
1234
741
510
427
4086
699
551
315
203
400
126
458
8069
168
436
Controls
954
95
848
1931
70
876
251
327
71
999
511
502
118
5537
1429
424
897
1388
1778
130
662
1378
0.15
0.15
0.08
0.10
0.08
0.09
0.07
0.09
0.08
0.09
0.09
0.09
0.08
0.09
0.08
0.06
MAF
0.09
0.07
0.09
0.09
0.06
0.10
0.21
0.07
0.09
0.09
0.08
0.10
0.09
0.09
0.08
0.09
0.09
0.09
0.08
0.10
0.08
0.08
0.98 (0.94, 1.01)
0.90 (0.67, 1.22)
1.09 (0.91, 1.29)
1.03 (0.77, 1.37)
0.85 (0.62, 1.16)
1.09 (0.75, 1.57)
1.07 (0.94, 1.22)
1.39 (1.02, 1.91)
0.91 (0.67, 1.23)
1.36 (0.87, 2.14)
0.83 (0.48, 1.42)
0.95 (0.59, 1.52)
0.38 (0.12, 1.21)
1.07 (0.76, 1.52)
0.94 (0.87, 1.02)
1.20 (0.60, 2.40)
1.16 (0.78, 1.71)
OR (95% CI)
0.98 (0.75, 1.28)
1.24 (0.65, 2.37)
0.75 (0.57, 1.00)
0.95 (0.79, 1.14)
1.64 (0.36, 7.56)
0.82 (0.63, 1.06)
0.98 (0.69, 1.39)
1.02 (0.65, 1.58)
0.65 (0.25, 1.66)
1.08 (0.84, 1.39)
1.12 (0.83, 1.51)
0.79 (0.56, 1.12)
0.79 (0.37, 1.70)
0.90 (0.81, 1.01)
0.98 (0.79, 1.21)
0.99 (0.71, 1.39)
0.70 (0.50, 0.98)
1.08 (0.85, 1.37)
0.98 (0.81, 1.18)
1.08 (0.65, 1.78)
1.33 (0.98, 1.80)
0.93 (0.74, 1.16)
 
1.5 2A
Figure 1 Association of rs10235235 with breast cancer risk for women
AG (heterozygote) genotype (A) and GG (homozygote) genotype (B) with br
confidence intervals (CIs); square boxes, study-specific fixed-effects estimates;
95% CI. Vertical line, null effect (OR = 1.0); dashed vertical line, estimated hete
for six studies (CTS, DEMOKRITOS, kConFab/AOCS, NBCS, NBHS and RPCI) cou
cases or among controls in each of these studies (see Table S2 in Additional fAsian study (Table S2 in Additional file 1). There was no
clear evidence that this SNP was associated with breast
cancer risk for women of Asian ancestry (heterozygote
OR = 1.06, 95% CI = 0.76, 1.49) or African-American
ancestry (heterozygote and homozygote ORs were OR =
1.09, 95% CI = 0.90, 1.32 and OR = 0.94, 95% CI = 0.62,
1.42 respectively; Figure S1 in Additional file 1). This ana-
lysis, however, had low power to detect associations in
non-Europeans and these OR estimates were not incon-
sistent with the magnitude of the observed OR estimates
for European women (Phet = 0.51).
Stratifying cases by oestrogen receptor (Phet = 0.83) or
progesterone receptor (Phet = 0.19) status, tumour grade
(Phet = 0.63) or nodal involvement at diagnosis (Phet = 0.51)
showed no evidence of effect modification (Table 1). There
was some evidence of effect modification by morphology
(Phet = 0.03). For ductal cancers we estimated a very
modest reduction of risk for heterozygotes (ORhet =
0.98, 95% CI = 0.93, 1.02; P = 0.30) and a stronger, sig-
nificant reduction for homozygotes (ORhom = 0.74, 95%
CI = 0.61, 0.90; P = 0.003). For lobular cancers there was
no such trend (ORhet = 1.07, 95% CI = 0.98, 1.17; P = 0.14
and ORhom = 0.91, 95% CI = 0.64, 1.27; P = 0.57).
The SNP rs10235235 maps to a locus (CYP3A) that
has been considered an a priori candidate for involve-
ment in determining age at menopause and age at me-
narche [21,22]. Stratifying cases by age at diagnosis (≤50Overall  (I-squared = 0.0%, phet = 0.76)
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Table 1 Association of rs10235235 with risk of breast cancer for women of European ancestry: stratified analysis
Cases Controls ORhet 95% CI P1 ORhom 95% CI P1 Phet
ER status
ER-positive 24,780 38,739 0.99 0.95, 1.03 0.61 0.83 0.70, 0.99 0.04
ER-negative 5,851 38,739 1.02 0.95, 1.10 0.60 0.60 0.43, 0.86 0.005
NK 8,339
Total 38,970a 38,739 0.99 0.95, 1.03 0.74 0.79 0.67, 0.94 0.006 0.83
PR status
PR-positive 18,497 39,033 0.98 0.93, 1.02 0.32 0.82 0.67, 0.99 0.04
PR-negative 8,193 39,033 1.02 0.96, 1.09 0.53 0.74 0.56, 0.98 0.03
NK 12,111
Total 38,801b 39,033 0.99 0.94, 1.03 0.52 0.80 0.67, 0.95 0.01 0.19
Morphology
Ductal 22,123 31,803 0.98 0.93, 1.02 0.30 0.74 0.61, 0.90 0.003
Lobular 3,921 31,803 1.07 0.98, 1.17 0.14 0.91 0.64, 1.27 0.57
Other and NK 5,995
Total 32,039 31,803 0.99 0.95, 1.04 0.64 0.77 0.64, 0.92 0.004 0.03
Grade
Grade 1 5,944 37,285 0.97 0.90, 1.05 0.46 0.86 0.65, 1.15 0.31
Grade 2 13,427 37,285 1.00 0.95, 1.06 0.92 0.80 0.63, 0.98 0.04
Grade 3 8,638 37,285 0.98 0.92, 1.05 0.58 0.61 0.46, 0.82 0.001
NK 8,769
Total 36,778 37,285 0.99 0.95, 1.03 0.56 0.76 0.64, 0.90 0.001 0.63
Nodal status
Node-negative 17,463 37,836 0.98 0.93, 1.03 0.47 0.86 0.71, 1.04 0.12
Node-positive 10,746 37,836 0.98 0.92, 1.04 0.46 0.72 0.57, 0.93 0.01
NK 9,359
Total 37,568 37,836 0.98 0.94, 1.02 0.31 0.81 0.68, 0.96 0.02 0.51
Association of rs10235235 with risk of breast cancer for women of European ancestry stratified by oestrogen receptor (ER) status, progesterone receptor (PR)
status, morphology, grade and nodal status. ORhet, odds ratio comparing rs10235235 AG genotype versus AA genotype; H0, null hypothesis; NK, not known;
ORhom, odds ratio comparing rs10235235 GG genotype versus AA genotype; P1, test of H0 no association between rs10235235 and breast cancer risk; Phet, test of
H0 no difference between stratum specific estimates for variables with two strata or test of H0 no linear trend in stratum specific estimates for variables with three
strata. aExcludes seven studies that selected all ER-negative cases (CTS, DEMOKRITOS, NBCS, NBHS, OSU, RPCI and SKKDKFZS) and one study (PBCS) that selected
all ER-positive cases. bExcludes seven studies that selected all PR-negative cases (CTS, DEMOKRITOS, NBCS, NBHS, OSU, RPCI and SKKDKFZS).
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sis showed no evidence of effect modification (Phet = 0.89;
Table 2), and excluding cases who were diagnosed between
age 46 and 55 as potentially perimenopausal did not alter
this result (Phet = 0.28). Data on age at menarche were
available for 21,736 cases and 22,686 controls (Table S4 in
Additional file 1); to increase the power of the analysis
we included additional data from BBCS and UKBGS
(5,737 cases, 5,572 controls; Table S4 in Additional file 1)
[19]. There was a 1.5% (95% CI = 0.5%, 2.7%; P = 0.004)
reduction in breast cancer risk associated with each
additional year’s increase in age at menarche. Mean age
at menarche was positively associated with number of
copies of the minor allele of rs10235235 for controls
(Ptrend = 0.005; Table 3) but not for cases (Ptrend = 0.97;
Table 3). Consequently, there was an inverse trend inthe magnitude of the heterozygote and homozygote
breast cancer ORs with mean age at menarche (Phet =
0.02; Table 4); being a carrier of one or two rare alleles
of rs10235235 was associated with an estimated 16%
(ORhet = 0.84, 95% CI = 0.75, 0.94; P = 0.003) or 19%
(ORhom = 0.81, 95% CI = 0.51, 1.30; P = 0.39) (Ptrend =
0.002) reduction in breast cancer risk for women who
had their menarche at ages ≥15 years but there was no
evidence of reduction for those with a menarche at
age ≤11 years (ORhet = 1.06, 95% CI = 0.95, 1.19; P = 0.30
and ORhom = 1.07, 95% CI = 0.67, 1.72; P = 0.78) (Ptrend =
0.29). There was no evidence that the inverse trend in
the magnitude of ORs with mean age at menarche dif-
fered between heterozygous and homozygous carriers
(P = 0.97) and no evidence that the trend was nonlinear
(P = 0.70).
Table 2 rs10235235 and risk of breast cancer for women of European ancestry by age at diagnosis
Age at diagnosis Casesa Controlsa ORhet 95% CI P1 ORhom 95% CI P1 Phet
≤ 50 years 11,794 34,988 0.99 0.93, 1.05 0.69 0.68 0.53, 0.86 0.003
> 50 years 23,264 34,988 0.97 0.93, 1.02 0.24 0.84 0.70, 1.00 0.04
NK 554
Total 35,612 34,988 0.98 0.94, 1.02 0.23 0.79 0.67, 0.92 0.003 0.89
aFive studies (ABCFS, MARIE, MEC, MTLGEBCS and SASBAC) that selected all cases on the basis of age at diagnosis (Table S3 in Additional file 1) were excluded
from this stratified analysis; two small studies (CTS and NBCS) that had no heterozygote or rare homozygote cases in one of the age stratum were also excluded.
H0, null hypothesis; NK, not known; ORhet, odds ratio comparing rs10235235 AG genotype versus AA genotype; ORhom, odds ratio comparing rs10235235 GG
genotype versus AA genotype; P1, test of H0 no association between rs10235235 and breast cancer risk; Phet, test of H0 no difference between stratum
specific estimates.
Johnson et al. Breast Cancer Research 2014, 16:R51 Page 7 of 13
http://breast-cancer-research.com/content/16/3/R51Discussion
This study of more than 47,000 breast cancer cases and
47,000 controls has confirmed that rs10235235, mapping
to 7q22.1 (CYP3A), is associated with a reduction in breast
cancer risk for women of European ancestry. Previously,
our hypothesis-generating study of 10,000 breast cancer
cases and 17,000 controls found a per-allele OR estimate
of 0.96 (95% CI = 0.90, 1.02; P = 0.2), with marginally sig-
nificant evidence of an inverse association for breast cancer
diagnosed age 50 years or younger (OR = 0.91, 95% CI =
0.83, 0.99; P = 0.03) but no evidence of an association for
breast cancer at later ages (OR = 1.01, 95% CI = 0.93, 1.10;
P = 0.82) [19]. In this considerably larger study, we found a
heterozygote OR estimate of 0.98 (95% CI = 0.94, 1.01;
P = 0.21) and a homozygote OR estimate of 0.80 (95%
CI = 0.69, 0.93; P = 0.004) with marginally significant
evidence that the inverse association for homozygotes is
greater than predicted by a multiplicative model (P = 0.04).
To our knowledge, rs10235235 is the first SNP to be
associated with both breast cancer risk and age at me-
narche, consistent with the well-documented association
between later age at menarche and a reduction in breast
cancer risk [23]. Genome-wide association studies have
identified more than 70 breast cancer risk variants [5,6]
and more than 30 variants associated with age at menar-
che [22], none of which map to the CYP3A locus.
rs10235235 was originally identified on the basis of a
highly significant association with hormone levels, ac-
counting for 4.9% of the variation in premenopausal
urinary oestrone glucuronide levels [19]. In this current
analysis, rs10235235 accounted for only 0.01% of the
variation across controls in age at menarche and we esti-
mate that this SNP explains just 0.01% of the familialTable 3 Association of rs10235235 with age at menarche for
rs10235235 genotype Cases Age at menarche (years)
AA 22,954 12.83
AG 4,312 12.83
GG 207 12.83
Total 27,473 12.83
H0, null hypothesis; Ptrend, test of H0 no linear trend in age at menarche according to rsexcess breast cancer risk. Our data thus illustrate the po-
tential statistical efficiency of studies of intermediate
phenotypes in the identification of rarer (MAF < 10%)
risk alleles with modest associations. Our analysis shows
some inconsistency with a recent genome-wide study of
circulating oestradiol, testosterone and sex hormone-
binding globulin in postmenopausal women [24]. In that
study there was no genome-wide significant association
observed with plasma oestradiol levels in either the pri-
mary analysis of approximately 1,600 postmenopausal
women who were not taking postmenopausal hormones
at blood draw or the secondary analysis that included
approximately 900 current postmenopausal hormone
users. Further studies will be needed to determine whether
the lack of an association between CYP3A variants and
postmenopausal plasma oestradiol levels reflects a differ-
ence in the menopausal status of the study subjects, the
hormone/metabolite that was analysed or chance.
One possible explanation for the apparent effect modi-
fication of the rs10235235–breast cancer risk association
by age at menarche is that this is a function of genotyp-
ing a marker SNP rather than the true causal variant.
For example, if rs10235235 was perfectly correlated with
a causal variant, SNP X, with a MAF substantially lower
than that of rs10235235 (D′ ~ 1.0, r2 < 1.0), then there
would be three types of chromosome in the population:
type i, chromosomes carrying the common allele of
rs10235235 and the common allele of SNP X; type ii,
chromosomes carrying the rare allele of rs10235235 and
the common allele of SNP X; and type iii, chromosomes
carrying the rare allele of rs10235235 and the rare (pro-
tective) allele of SNP X. Only chromosomes carrying the
rare allele of rs10235235 and the rare (protective) allele ofwomen of European ancestry by case-control status
Ptrend Controls Age at menarche (years) Ptrend
23,383 12.95
4,627 13.02
248 13.05
0.97 28,258 12.96 0.005
10235235 genotype.
Table 4 rs10235235 and risk of breast cancer for women of European ancestry by age at menarche
Age at menarche (years) Cases Controls ORhet 95% CI P1 ORhom 95% CI P1 Phet
≤11 4,818 4,749 1.06 0.95, 1.19 0.30 1.07 0.67, 1.72 0.78
12 5,655 5,720 0.92 0.83, 1.02 0.10 0.83 0.54, 1.28 0.41
13 7,308 7,379 0.93 0.85, 1.02 0.11 0.77 0.54, 1.09 0.14
14 5,307 5,743 0.96 0.86, 1.06 0.42 0.69 0.45, 1.06 0.09
≥15 4,385 4,667 0.84 0.75, 0.94 0.003 0.81 0.51, 1.30 0.39
Total 27,473 28,258 0.94 0.90, 0.98 0.007 0.81 0.67, 0.98 0.03 0.02
H0, null hypothesis; ORhet, odds ratio comparing rs10235235 AG genotype versus AA genotype; ORhom, odds ratio comparing rs10235235 GG genotype versus AA
genotype; P1, test of H0 no association between rs10235235 and breast cancer risk; Phet, test of H0 no linear trend in stratum specific estimates.
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ing the marker (rs10235235) rather than the causal variant
leads to misclassification. As the causal variant is associ-
ated with a protective effect on breast cancer risk, the pro-
portion of chromosomes carrying both the rare allele of
the causal variant and the marker (type iii) compared with
the common allele of the causal variant and the rare allele
of the marker (type ii) will be greater in controls than in
cases such that the extent of misclassification will be
greater for cases than controls. This will attenuate the as-
sociation between genotype and age at menarche to a
greater extent in cases than in controls creating an appar-
ent effect modification. Fine mapping and functional stud-
ies will be required to identify the causal variant and to
determine the true relationship between the causal vari-
ant, age at menarche and breast cancer risk.
Despite our original finding of a strong association be-
tween rs10235235 and hormone levels, we found no evi-
dence that the association between this SNP and breast
cancer risk differed by the hormone receptor status of the
tumour, and nor did we find any evidence that the associ-
ation differed by stage, grade or lymph node involvement.
There was marginally significant evidence that the associ-
ation between rs10235235 and breast cancer risk differed
between ductal and lobular cancers (Phet = 0.03). Given
the number of stratified analyses that we carried out (six
stratifying variables) and given that there is no biological
basis to support an interaction between rs10235235 and
morphology, this is probably a chance observation.
In contrast to our earlier study [19], we found no evi-
dence of an interaction with age at diagnosis when we
stratified cases by age ≤/>50 years, either including or
excluding cases diagnosed between age 46 and 55 years
as potentially perimenopausal. We used age at diagnosis
as a proxy for menopausal status at diagnosis because
menopausal status at diagnosis is difficult to determine
by questionnaire, especially given the use of hormone
replacement therapies; while information on age at
diagnosis was available for all but 1.4% (n = 554) of
cases, information on age at natural menopause was
missing for 65.6% (n = 26,552) of cases of Europeanancestry. Similarly, although rs10235235 is a plausible
candidate for association with age at menopause, we
did not test this due to the limited amount of data on
age at natural menopause for controls of European an-
cestry (n = 11,294, 28.2%) and the difficulty in ascertaining
whether treatment for breast cancer had influenced re-
ported age at menopause for cases.
The strengths of our study include the large size of
this combined analysis, and the availability of informa-
tion on tumour characteristics for the majority of cases
and on age at menarche for the majority of cases and
controls. Limitations include low power of the study to
examine an association between genotype and breast
cancer risk for non-Europeans.
Conclusions
In summary, we have confirmed that rs10235235 is asso-
ciated with breast cancer, have shown for the first time
that rs10235235 is associated with age at menarche in
controls and have suggested a potential mechanism for
these associations. rs10235235, which maps to the
CYP3A locus, probably tags a causal variant that affects
expression of one or more CYP3A genes.
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